☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
karuna therapeutics
Karuna Therapeutics Reports the NDA Submission of KarXT to the US FDA for the Treatment of Schizophrenia
September 28, 2023
Karuna Therapeutics Entered into an Exclusive License Agreement with Goldfinch Bio for TRPC4/5 Product Candidates
February 2, 2023
PharmaShots Weekly Snapshots (November 08, 12, 2021)
November 12, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.